Massimo Tommasino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Massimo Tommasino has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Assunta Venuti
International Agency for Research on Cancer (IARC), World Health Organization, 69366 Lyon, CEDEX 07, France
1 shared publication - Sigrun Smola
Institute of Virology, Saarland University Medical Center, D-66421 Homburg, Germany
1 shared publication - Stefan Lohse
Institute of Virology, University of Saarland, Homburg, Germany
1 shared publication
Latest Publications
- Open Access
- 8 April 2019
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 374 (1773) , 20180287
Cross-talk of cutaneous beta human papillomaviruses and the immune system: determinants of disease penetrance
Human papillomaviruses (HPVs) infect the epithelia of skin or mucosa, where they can induce hyperproliferative lesions. More than 220 different HPV types have been characterized and classified into five different genera. Mucosal high-risk HPVs are causative for cancers of the anogenital region and oropharynx. Clinical data from patients with the rare genetic disorder epidermodysplasia verruciformis (EV) indicate that genus beta-HPVs cooperate with ultraviolet (UV) radiation in the development of cutaneous squamous cell carcinoma. In addition, epidemiological and biological findings indicate that beta-HPV types play a role in UV-mediated skin carcinogenesis also in non-EV individuals. However, the mechanisms used by these cutaneous viruses to promote epithelial carcinogenesis differ significantly from those of mucosal HPVs. Recent studies point to a delicate cross-talk of beta-HPVs with the cell-autonomous immunity of the host keratinocytes and the local immune microenvironment that eventually determines the fate of cutaneous HPV infection and the penetrance of disease. This review gives an overview of the critical interactions of genus beta-HPVs with the local immune system that allow the virus to complete its life cycle, to escape from extrinsic immunity, and eventually to cause chronic inflammation contributing to skin carcinogenesis. This article is part of the theme issue ‘Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses’.
- 8 April 2019
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 374 (1773) , 20180287
Open AccessCross-talk of cutaneous beta human papillomaviruses and the immune system: determinants of disease penetrance
Human papillomaviruses (HPVs) infect the epithelia of skin or mucosa, where they can induce hyperproliferative lesions. More than 220 different HPV types have been characterized and classified into five different genera. Mucosal high-risk HPVs are causative for cancers of the anogenital region and oropharynx. Clinical data from patients with the rare genetic disorder epidermodysplasia verruciformis (EV) indicate that genus beta-HPVs cooperate with ultraviolet (UV) radiation in the development of cutaneous squamous cell carcinoma. In addition, epidemiological and biological findings indicate that beta-HPV types play a role in UV-mediated skin carcinogenesis also in non-EV individuals. However, the mechanisms used by these cutaneous viruses to promote epithelial carcinogenesis differ significantly from those of mucosal HPVs. Recent studies point to a delicate cross-talk of beta-HPVs with the cell-autonomous immunity of the host keratinocytes and the local immune microenvironment that eventually determines the fate of cutaneous HPV infection and the penetrance of disease. This review gives an overview of the critical interactions of genus beta-HPVs with the local immune system that allow the virus to complete its life cycle, to escape from extrinsic immunity, and eventually to cause chronic inflammation contributing to skin carcinogenesis. This article is part of the theme issue ‘Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses’.